These data require reflection on potential mechanisms by which antiangiogenic therapy could augment benefit associated with current approaches, and identify mechanisms that may limit the ability of ...

Antiangiogenic agents have been shown to prune some tumor vessels and 'normalize' the structure and function of the remaining vasculature, thereby improving the access of chemotherapeutic agents ...

5: VEGF Inhibition in NSCLC July 18th 2018EP. 7: Future Use of Antiangiogenic Agents in NSCLC July 18th 2018EP. 8: Evidence for Immunotherapy in Frontline NSCLC July 18th 2018EP. 9: Considerations ...

In their report published online in PNAS Early Edition, the investigators describe how preoperative treatment with the antiangiogenic drug bevacizumab primarily benefited patients whose tumors ...

Researchers have just published an important finding regarding antiangiogenic drugs. In the article they describe a resistance mechanism to these compounds and, more importantly, a way to reverse it.

Antiangiogenic drugs specifically block this process. This type of therapy usually has good short-term results, reducing tumor growth. However, several studies suggest that these treatments ...

H. Jack West, MD: I think one of the interesting and challenging things about antiangiogenic therapy is that we aren’t entirely sure how these agents work in practice. There are preclinical data ...

Considerations regarding the modes and underlying mechanisms of resistance to antiangiogenic therapy present both the directionality of future research and the outlines of a strategy for improving ...

How brain tumors escape the effects of antiangiogenic drugs Tumor co-option of existing blood vessels may be a new treatment target Date: January 30, 2019 Source: Massachusetts General Hospital ...

But, in February 22 Science, Joanne Yu and colleagues from University of Toronto, Canada, show that p53 loss in tumor cells confers a resistance to hypoxia that might reduce the efficacy of ...

Aim: This study examines the effect of combining the antiangiogenic effect of α v β 3-targeted fumagillin nanoparticles with the conventional antirheumatic drug methotrexate for the treatment of ...